BlackRock
BCYC

BlackRock’s Bicycle Therapeutics BCYC Stock Holding History

BlackRock’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.19M Buy
280,386
+1,394
+0.5% +$6.39K ﹤0.01% 4306
2026
Q1 		$1.29M Sell
278,992
-53,897
-16% -$308K ﹤0.01% 4246
2025
Q4 		$2.36M Buy
332,889
+50,471
+18% +$372K ﹤0.01% 4075
2025
Q3 		$2.19M Buy
282,418
+18,070
+7% +$136K ﹤0.01% 4065
2025
Q2 		$1.84M Sell
264,348
-58,528
-18% -$466K ﹤0.01% 4080
2025
Q1 		$2.74M Sell
322,876
-42,532
-12% -$501K ﹤0.01% 3895
2024
Q4 		$5.12M Sell
365,408
-54,355
-13% -$1.16M ﹤0.01% 3723
2024
Q3 		$9.5M Buy
419,763
+17,540
+4% +$405K ﹤0.01% 3436
2024
Q2 		$8.14M Sell
402,223
-172,807
-30% -$3.9M ﹤0.01% 3491
2024
Q1 		$14.3M Buy
575,030
+73,407
+15% +$1.56M ﹤0.01% 3168
2023
Q4 		$9.07M Buy
501,623
+307,539
+158% +$5.09M ﹤0.01% 3445
2023
Q3 		$3.9M Buy
194,084
+12,976
+7% +$297K ﹤0.01% 3757
2023
Q2 		$4.62M Buy
181,108
+2,176
+1% +$50.5K ﹤0.01% 3751
2023
Q1 		$3.81M Sell
178,932
-10,886
-6% -$273K ﹤0.01% 3754
2022
Q4 		$5.62M Buy
189,818
+8,771
+5% +$235K ﹤0.01% 3672
2022
Q3 		$4.21M Sell
181,047
-10,059
-5% -$239K ﹤0.01% 3828
2022
Q2 		$3.21M Buy
191,106
+977
+0.5% +$20.6K ﹤0.01% 4021
2022
Q1 		$8.34M Sell
190,129
-13,866
-7% -$648K ﹤0.01% 3672
2021
Q4 		$12.4M Buy
+203,995
New +$11.3M ﹤0.01% 3544

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
GP
GSK plc London $602M AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

BlackRock's BCYC Position: Q2 2026 in Review

BlackRock increased its Bicycle Therapeutics (BCYC) stake by 0.5% in Q2 2026, buying an estimated $6.39K and bringing the position to 280,386 shares worth $1.19M. The position accounts for ﹤0.01% of the portfolio, ranked #4306.

BlackRock first reported a position in BCYC in Q4 2021 and has held it in 19 quarters since. The position peaked at $14.3M in Q1 2024. 104 funds tracked by Wall St. Rank hold BCYC as of Q2 2026.

  • BlackRock held 280,386 shares of Bicycle Therapeutics worth $1.19M as of Q2 2026.
  • BlackRock bought 1,394 Bicycle Therapeutics shares in Q2 2026, an estimated $6.39K.
  • Bicycle Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4306 holding.
  • BlackRock first reported a position in Bicycle Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • BlackRock's Bicycle Therapeutics position peaked at $14.3M in Q1 2024.
  • 104 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.